Glutaraldehyde treatment of allograft tissue decreases allosensitization after the Norwood procedure.
OBJECTIVE
Cryopreserved allograft tissue used in the Norwood procedure for infants with hypoplastic left heart syndrome causes a marked immunologic sensitization that may complicate future heart transplantation. Treatment of the allograft tissue before implantation may prevent this sensitization. The purpose of this study was to assess the anti-human leukocyte antigen antibody response to glutaraldehyde-treated allograft tissue used in the repair of hypoplastic left heart syndrome.


METHODS
Since June 2005, the University of Alberta has subjected allograft vascular tissue used in the Norwood procedure to glutaraldehyde treatment. An observational study was designed to assess whether glutaraldehyde treatment of the allograft tissue affected subsequent panel reactive antibody after patch implantation. Panel reactive antibodies for class I (human leukocyte antigen-A, B, C) and class II (human leukocyte antigen-DR, DQ) antibodies were measured 4 months postoperatively using flow cytometry.


RESULTS
Fourteen patients underwent a Norwood procedure using glutaraldehyde-treated allograft tissue. Historical controls consisted of 12 patients who underwent a Norwood procedure using untreated allograft tissue. At 4 months, infants who had received glutaraldehyde-treated allograft tissue had lower class I panel reactive antibody (7.3% +/- 17.4% [median, 0%] vs 61.9% [median, 73%] +/- 39.9%; P = .0005) and class II panel reactive antibody (6.1% [median, 0%] +/- 22.7% vs 49.3% [median, 63%] +/- 41.9%, P = .001) compared with the historical controls.


CONCLUSIONS
Intraoperative glutaraldehyde treatment of allograft tissue used in hypoplastic left heart syndrome repair prevents the profound immunologic sensitization that occurs in the majority of infants undergoing surgical palliation. In patients requiring subsequent heart transplantation, this decreases the risk of antibody-mediated rejection and increases the likelihood of finding a suitable donor, thus improving access to transplantation.
Laing
Bryce J
BJ
Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Ross
David B
DB
Meyer
Steven R
SR
Campbell
Patricia
P
Halpin
Anne M
AM
West
Lori J
LJ
Rebeyka
Ivan M
IM
D015331:Cohort Studies; D015925:Cryopreservation; D005260:Female; D005976:Glutaral / Q000008:administration & dosage; D006801:Humans; D006967:Hypersensitivity / Q000209:etiology / Q000517:prevention & control*; D018636:Hypoplastic Left Heart Syndrome / Q000601:surgery*; D007231:Infant, Newborn; D008297:Male; D011300:Preoperative Care; D011651:Pulmonary Artery / Q000637:transplantation*; D016378:Tissue Transplantation / Q000009:adverse effects
D005976:Glutaral